13-THY-03-AZ (D4203C00011) [VERIFY]Phase III Study of Vandetanib in Advanced Radioiodine Refractory Thyroid Cancers

Ain, Kenneth (PI)

Markey Cancer Center / Cancer Research Priority Initiative

Status	Finished
Effective start/end date	7/1/17 → 11/29/21

Funding

Genzyme Corp: $54,970.00

1 Finished

Residual Scope: 13-THY-03-AZ (D4203C00011) [VERIFY]Phase III Study of Vandetanib in Advanced Radioiodine Refractory Thyroid Cancers
Ain, K.
Genzyme Corp
7/1/17 → 11/29/21
Project: Research project